Effects of pharmacological entopeduncular manipulations on idiopathic dystonia in the dt(sz) mutant hamster.
The pathophysiology of idiopathic dystonias is still unknown, but it is regarded as a basal ganglia disorder. Previous experiments in the dt(sz) hamster, a model of primary paroxysmal dystonia, demonstrated reduced discharge rates and an abnormal pattern within the entopeduncular nucleus (EPN), a basal ganglia output structure. To clarify if this is based on abnormal gamma-aminobutyric acid(GABA)ergic or glutamatergic input, microinjections into the EPN were done in mutant hamsters in the present study. The GABA(A) receptor antagonists pentylenetetrazole and bicuculline exerted moderate antidystonic effects, while previous systemic administrations worsened dystonia in the dt(sz) mutant. GABA-potentiating drugs, i.e., the GABA(A) receptor agonist muscimol and the GABA transporter inhibitor 1,2,5,6-tetrahydro-1-[2-[[(diphenylmethylene)amino]oxy]ethyl]-3-pyridinecarboxy-lic acid (NNC-711), which are known to improve dystonia after systemic treatment in mutant hamsters, did not exert significant effects after EPN injections, but NNC-711 tended to increase the severity at the highest dose (2.5 ng bilateral). The NMDA receptor antagonist D(-)-2-amino-5-phosphopentanoic acid (AP-5) retarded the onset of a dystonic attack. However, this effect was not dose dependent and the AMPA receptor antagonist 2,3-dihydroxy-6-nitro-7-sulfamoylbenzol(f)quinoxaline (NBQX) alone or in combination with AP-5 and NNC-711, also failed to show any effects on dystonia. The present data do not provide clear evidence for an enhanced striatal GABAergic input or a reduced glutamatergic activation of the EPN via the subthalamic nucleus, i.e., more pronounced antidystonic effects of GABA(A) receptor antagonists and stronger prodystonic effects of GABAmimetics and glutamate receptor antagonists were expected. Nevertheless, previously found changes in entopeduncular activity probably play a critical pathophysiological role in dystonic hamsters.
Hamann
Melanie
M
Department of Veterinary Medicine, Institute of Pharmacology and Toxicology, Freie Universität Berlin, Koserstr. 20, 14195 Berlin, Germany. Hamann.Melanie@vetmed.fu-berlin.de
Sander
Svenja E
SE
Kreil
Annette
A
Richter
Angelika
A
D000818:Animals; D000831:Animals, Newborn; D006224:Cricetinae; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D004421:Dystonia / Q000139:chemically induced / Q000188:drug therapy / Q000235:genetics / Q000473:pathology*; D020392:Entopeduncular Nucleus / Q000187:drug effects* / Q000503:physiopathology*; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology*; D018682:GABA Agents / Q000494:pharmacology*; D008845:Microinjections / Q000379:methods; D009118:Muscimol / Q000494:pharmacology; D009557:Nipecotic Acids / Q000494:pharmacology; D010091:Oximes / Q000494:pharmacology; D010433:Pentylenetetrazole / Q000494:pharmacology; D011810:Quinoxalines / Q000494:pharmacology; D011930:Reaction Time / Q000187:drug effects; D012720:Severity of Illness Index; D013997:Time Factors; D014633:Valine / Q000031:analogs & derivatives / Q000494:pharmacology
D018691:Excitatory Amino Acid Antagonists; D018682:GABA Agents; D009557:Nipecotic Acids; D010091:Oximes; D011810:Quinoxalines; C062865:2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline; C078793:NNC 711; D009118:Muscimol; C056639:2-amino-5-phosphopentanoic acid; D014633:Valine; D010433:Pentylenetetrazole
Prog Neurobiol. 1998 Dec;56(5):507-40
9775402
J Neurosci. 2008 Dec 17;28(51):13967-77
19091985
Exp Brain Res. 1994;102(2):244-58
7705503
Neurobiol Dis. 2010 May;38(2):288-98
20138992
Eur J Pharmacol. 2002 May 17;443(1-3):59-70
12044793
Mov Disord. 2006 Oct;21(10):1566-77
16830313
Eur J Pharmacol. 1993 Feb 9;231(2):287-91
8384114
Neuropathol Appl Neurobiol. 2006 Feb;32(1):74-82
16409555
J Neurosci. 2001 Jul 1;21(13):RC153
11406638
J Neuropathol Exp Neurol. 2005 Sep;64(9):776-81
16141787
Brain Res. 2004 May 15;1008(1):126-30
15081391
J Neurosci. 2009 Jun 17;29(24):7797-802
19535591
Eur J Pharmacol. 1992 Dec 2;224(2-3):189-98
1468507
Eur J Pharmacol. 2007 Jun 1;563(1-3):102-8
17349621
J Pharmacol Exp Ther. 2008 Aug;326(2):646-56
18451317
Brain Res. 1999 Mar 13;821(2):277-85
10064814
Eur J Pharmacol. 2005 Oct 3;521(1-3):95-8
16183056
Neurobiol Dis. 2009 Sep;35(3):399-405
19501651
Neurobiol Aging. 1994 Mar-Apr;15(2):259-60
7838306
J Neurophysiol. 2005 Jun;93(6):3165-76
15703229
Nat Rev Neurosci. 2008 Mar;9(3):222-34
18285800
Brain Res. 2007 May 30;1150:190-9
17391652
Ann Neurol. 1999 Jul;46(1):22-35
10401777
Parkinsonism Relat Disord. 2007;13 Suppl 3:S362-8
18267265
J Comp Neurol. 2000 Oct 23;426(3):366-77
10992243
Adv Neurol. 1998;78:1-10
9750897
Neurochem Res. 1996 Oct;21(10):1201-7
8923481
J Neurosci. 2000 Sep 15;20(18):7052-8
10995851
J Neurosci Res. 2009 Feb 15;87(3):776-83
18831004
Clin Neurophysiol. 2004 Jun;115(6):1239-48
15134690
Eur J Pharmacol. 2002 May 3;442(1-2):81-92
12020685
J Neurosci. 2002 Aug 15;22(16):7244-53
12177219
Prog Neurobiol. 1998 Apr;54(6):633-77
9560845
Neurotherapeutics. 2008 Apr;5(2):281-93
18394570
Curr Med Chem. 2000 Oct;7(10):1063-79
10911018
Prog Brain Res. 2007;160:287-312
17499121
Pharmacology. 2007;80(2-3):127-33
17534122
Acta Neurochir Suppl. 2007;97(Pt 2):191-9
17691304
NeuroRx. 2005 Jul;2(3):504-12
16389314
J Neurophysiol. 2007 Apr;97(4):2627-41
17215512
Neuroreport. 2004 Jun 28;15(9):1391-3
15194859